2026-04-13T07:10:45Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4785812025-10-28T12:25:26Zcom_2072_98col_2072_378192

urn:hdl:2072/478581 Combined Reporting of Surgical Quality and Cancer Control after Surgical Treatment for Penile Tumors with Inguinal Lymph Node Dissection : The Tetrafecta Achievement Brassetti, Aldo Anceschi, Umberto Cozzi, Gabriele Chavarriaga, Julian Gavrilov, Pavel Gaya Sopena, Josep Maria Bove, Alfredo Maria Prata, Francesco Ferriero, Mariaconsiglia Mastroianni, Riccardo Misuraca, Leonardo Tuderti, Gabriele Torregiani, Giulia Covotta, Marco Camacho, Diego Musi, Gennaro Varela, Rodolfo Breda, Alberto De Cobelli, Ottavio Simone, Giuseppe Universitat Autònoma de Barcelona Tetrafecta Inguinal lymphadenectomy Penile cancer Surgical quality Survival To optimize results reporting after penile cancer (PC) surgery, we proposed a Tetrafecta and assessed its ability to predict overall survival (OS) probabilities. A purpose-built multicenter, multi-national database was queried for stage I-IIIB PC, requiring inguinal lymphadenectomy (ILND), from 2015 onwards. Kaplan-Meier (KM) method assessed differences in OS between patients achieving Tetrafecta or not. Univariable and multivariable regression analyses identified its predictors. A total of 154 patients were included in the analysis. The 45 patients (29%) that achieved the Tetrafecta were younger (59 vs. 62 years; p = 0.01) and presented with fewer comorbidities (ASA score ≥ 3: 0% vs. 24%; p < 0.001). Although indicated, ILND was omitted in 8 cases (5%), while in 16, a modified template was properly used. Although median LNs yield was 17 (IQR: 11-27), 35% of the patients had <7 nodes retrieved from the groin. At Kaplan-Maier analysis, the Tetrafecta cohort displayed significantly higher OS probabilities (Log Rank = 0.01). Uni- and multivariable logistic regression analyses identified age as the only independent predictor of Tetrafecta achievement (OR: 0.97; 95%CI: 0.94-0.99; p = 0.04). Our Tetrafecta is the first combined outcome to comprehensively report results after PC surgery. It is widely applicable, based on standardized and reproducible variables and it predicts all-cause mortality. 2023 Article Current Oncology ; Vol. 30 Núm. 2 (february 2023), p. 1882-1892 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/